Myositis is inflammation of the muscles you use to move your body. It causes progressive muscle weakness that can make everyday tasks like climbing stairs, lifting objects, or even swallowing difficult. Myositis is relatively rare, affecting roughly 2 to 34 people per 100,000 depending on the subtype and population studied, and it’s slightly more common in women than men.
The condition can be triggered by infections, injuries, or, most commonly in chronic cases, an autoimmune process where the immune system mistakenly attacks healthy muscle tissue. When doctors refer to myositis without further context, they typically mean the autoimmune forms, collectively called idiopathic inflammatory myopathies.
Types of Myositis
There are four main types of chronic inflammatory myositis, each with a distinct pattern of muscle involvement and progression.
Polymyositis affects the skeletal muscles on both sides of the body, particularly those closest to your trunk. You might notice difficulty standing up from a chair, climbing stairs, lifting things overhead, or reaching for objects on a high shelf. It tends to develop gradually over weeks to months.
Dermatomyositis causes the same kind of progressive muscle weakness as polymyositis but also involves the skin. A distinctive rash often appears on the eyelids, knuckles, elbows, or knees. This form carries a notably higher association with cancer: roughly 10 to 30 percent of adults with dermatomyositis develop a malignancy within two to five years of diagnosis, most often in people over 40. Annual cancer screening is recommended for the first three years after diagnosis.
Inclusion body myositis (IBM) is the most distinct form. It primarily affects people over 50 and progresses slowly, sometimes over years before it’s even recognized. Unlike the other types, IBM tends to hit muscles asymmetrically and targets the hands and lower legs early on. The hallmark signs are weakness in the quadriceps (front of the thigh) and the finger flexors. People with IBM often notice a weakening grip, frequent tripping, foot drop, or knees that buckle unexpectedly. Weakness in the distal finger flexors, tested by trying to bend the fingertip joint, is often the earliest detectable finding.
Necrotizing autoimmune myopathy involves weakness in both the upper and lower body and is characterized by significant muscle cell damage. It can develop in association with certain medications or autoimmune triggers.
Common Symptoms
The defining symptom across all types of myositis is muscle weakness, not just soreness. You may feel like you can’t control your arms, hands, or legs the way you normally would, or you tire out unusually fast during physical activity. The muscles most commonly affected are those in your arms and shoulders, legs and hips, and the trunk of your body (abdomen and spine).
Beyond muscle weakness, myositis can cause joint or muscle pain, fatigue, and swelling. In more serious cases, it can affect muscles involved in swallowing (the esophagus and throat), breathing (the diaphragm), and even heart rhythm. Up to 30 percent of people with myositis develop difficulty swallowing, which can lead to choking or aspiration of food into the lungs.
What Causes It
In the autoimmune forms, the immune system produces antibodies and inflammatory cells that target muscle fibers, breaking them down over time. What triggers this immune misfiring isn’t fully understood, but researchers have identified specific autoantibodies linked to each subtype. For example, anti-Jo-1 antibodies are associated with a pattern called antisynthetase syndrome, which involves muscle inflammation along with lung and joint problems. Other antibodies correlate with different clinical pictures, helping doctors predict which organs might be at risk.
Non-autoimmune myositis can result from viral or bacterial infections, drug reactions, or direct muscle injury. These forms are generally more straightforward to treat once the underlying cause is addressed.
How Myositis Is Diagnosed
Diagnosis typically starts with blood tests measuring muscle enzymes, especially creatine kinase (CK). When muscle fibers are damaged, CK leaks into the bloodstream, so elevated levels point toward active muscle injury. In some forms, CK can spike above 5,000 IU/L (normal is usually under 200). However, CK isn’t a perfect marker. In certain types of dermatomyositis and in inclusion body myositis, CK levels can be only slightly elevated or even normal despite significant weakness.
Autoantibody testing plays an increasingly important role. Doctors now recognize over a dozen myositis-specific antibodies, each associated with distinct clinical patterns. Identifying which antibody a patient carries helps determine the subtype, predict complications, and guide treatment decisions. Beyond blood work, doctors may use muscle imaging, electrical testing of muscle function, or a muscle biopsy to confirm the diagnosis and rule out other conditions that mimic myositis.
Potential Complications
Myositis can affect more than just muscles. Interstitial lung disease (ILD), a condition where the lung tissue becomes scarred and stiff, is the most common complication and occurs in about 23 percent of Americans with dermatomyositis or polymyositis. Most cases follow a chronic, slowly progressing course, but a rapidly progressive form exists that carries mortality rates between 70 and 90 percent. Shortness of breath or a persistent cough should always be flagged to your doctor.
Swallowing difficulties, voice changes, and aspiration of food into the lungs are associated with a worse overall prognosis. Cardiac involvement, though less common, can cause irregular heart rhythms. The cancer link with dermatomyositis is significant enough that screening for common malignancies (including cancers of the lung, colon, breast, ovary, and blood) is a standard part of follow-up care. Notably, children with dermatomyositis almost never develop associated cancers, so screening in younger patients isn’t routine.
Treatment and What to Expect
High-dose corticosteroids remain the first-line treatment for most forms of inflammatory myositis. These medications work quickly to suppress the immune attack on muscle tissue. Doctors typically combine steroids with a second immune-suppressing medication early on, both to improve effectiveness and to allow steroid doses to be lowered sooner, since long-term steroid use carries its own health risks.
The specific immune-suppressing medication chosen depends on which organs are involved and how severe the disease is. For muscle-predominant disease, the most commonly used options target the overactive immune response at different points. In cases that don’t respond to standard treatment, infusions of pooled antibodies from donor blood (IVIG) can help modulate the immune system through a different mechanism. IVIG has shown particular benefit in dermatomyositis.
Inclusion body myositis is the exception. It responds poorly to immunosuppressive treatments, and management focuses more on physical therapy, fall prevention, and adaptive strategies to maintain function as long as possible.
Long-Term Outlook
For most people with inflammatory myositis, the outlook with treatment is favorable. In a study following patients for over two years, about 74 percent achieved a complete clinical response and nearly 12 percent had a partial response. Around 40 percent were eventually able to stop steroids entirely, and another half were maintained on very low doses. Fewer than 5 percent of patients in that cohort had significant disability at their last follow-up.
Full clinical remission, meaning disease is inactive and medications can be stopped, was achieved by about 14 percent of patients, typically after a median of five years. The disease course varies: roughly half of patients experience a chronic continuous pattern requiring ongoing treatment, about 37 percent have a relapsing-remitting course with flares and quiet periods, and around 14 percent have a single episode that resolves. The median time before a relapse occurred was about 10 years.
Myositis requires long-term follow-up even when things are going well. Complete discontinuation of steroids and achieving a full clinical response are both associated with better physical function and less accumulated damage over time. Physical rehabilitation plays an important role throughout the disease course, helping maintain strength, flexibility, and the ability to perform daily activities.